These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30785995)

  • 41. Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.
    Domínguez JM; Nilo F; Contreras T; Carmona R; Droppelmann N; González H; Iturrieta V; Tuttle RM
    J Ultrasound Med; 2017 Nov; 36(11):2299-2307. PubMed ID: 28543974
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The predictive value for excellent response to initial therapy in differentiated thyroid cancer: preablation-stimulated thyroglobulin better than the TNM stage.
    Zhang Y; Hua W; Zhang X; Peng J; Liang J; Gao Z
    Nucl Med Commun; 2018 May; 39(5):405-410. PubMed ID: 29557849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preablative Stimulated Thyroglobulin and Thyroglobulin Reduction Index as Decision-Making Markers for Second Radioactive Iodine Therapy in Patients with Structural Incomplete Response.
    Wang L; Yun C; Huang F; Xiao J; Ju Y; Cheng F; Zhang W; Jia H
    Cancer Manag Res; 2021; 13():5351-5360. PubMed ID: 34262343
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improving the prediction of persistent and recurrent differentiated thyroid cancer using the American Thyroid Association 2015 risk stratification system.
    Markantes GK; Karakioulaki M; Papanikolopoulou S; Theodoropoulou A; Markou KB; Vagenakis AG; Spyridonidis T; Goulis DG; Michalaki MA
    Hormones (Athens); 2021 Dec; 20(4):761-768. PubMed ID: 34383288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels.
    Pellegriti G; Scollo C; Regalbuto C; Attard M; Marozzi P; Vermiglio F; Violi MA; Cianci M; Vigneri R; Pezzino V; Squatrito S
    Clin Endocrinol (Oxf); 2003 May; 58(5):556-61. PubMed ID: 12699436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early stimulated thyroglobulin for response prediction after recombinant human thyrotropin-aided radioiodine therapy.
    Park HJ; Min JJ; Bom HS; Kim J; Song HC; Kwon SY
    Ann Nucl Med; 2017 Oct; 31(8):616-622. PubMed ID: 28688088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine.
    Nóbrega G; Cavalcanti M; Leite V; Vilar L; Brandão SCS
    Endocrine; 2022 Jun; 76(3):642-647. PubMed ID: 35237910
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes.
    Wijewardene A; Gill AJ; Gild M; Learoyd DL; Glover AR; Sywak M; Sidhu S; Roach P; Schembri G; Hoang J; Robinson B; Tacon L; Clifton-Bligh R
    Thyroid; 2022 Oct; 32(10):1201-1210. PubMed ID: 35620896
    [No Abstract]   [Full Text] [Related]  

  • 50. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.
    Chang YW; Kim HS; Jung SP; Kim HY; Lee JB; Bae JW; Son GS
    Int J Clin Oncol; 2016 Oct; 21(5):862-868. PubMed ID: 26837274
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation.
    Nascimento C; Borget I; Troalen F; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Chougnet CN; Baudin E; Schlumberger M; Leboulleux S
    Eur J Endocrinol; 2013 Nov; 169(5):689-93. PubMed ID: 23939918
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.
    Orlov S; Salari F; Kashat L; Freeman JL; Vescan A; Witterick IJ; Walfish PG
    Endocrine; 2015 Sep; 50(1):130-7. PubMed ID: 25792004
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recombinant human thyrotropin-stimulated thyroglobulin level at the time of radioactive iodine ablation is an independent prognostic marker of differentiated thyroid carcinoma in the setting of prophylactic central neck dissection.
    Moon JH; Choi JY; Jeong WJ; Ahn SH; Lee WW; Kim KM; Choi SH; Lim S; Park YJ; Yi KH; Park do J; Jang HC
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):459-65. PubMed ID: 26833982
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stimulated serum thyroglobulin but not RAIU level is a prognostic factor for ablation efficacy with a 3.7GBq (100mCi) fixed
    Xiao L; Wang Y; Huang R; Li L
    Hell J Nucl Med; 2021; 24(1):53-59. PubMed ID: 33866339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.
    Zhao T; Liang J; Guo Z; Li J; Lin Y
    Endocrine; 2016 Jul; 53(1):166-73. PubMed ID: 26782372
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the usefulness of post-ablative and post-operative thyroglobulin concentration measuring in prognostic assessment of patients with differentiated thyroid cancer.
    Gadawska-Juszczyk K; Kowalska A
    Endokrynol Pol; 2015; 66(6):486-94. PubMed ID: 26662647
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
    Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
    Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term outcome of differentiated thyroid cancer in children and young adults: risk stratification by ATA criteria and assessment of pre-ablation stimulated thyroglobulin as predictors of disease persistence.
    Karapanou O; Tzanela M; Rondogianni P; Dacou-Voutetakis C; Chiotis D; Vlassopoulou B; Vassiliadi D; Kanaka-Gantenbein C; Tsagarakis S
    Endocrine; 2020 Dec; 70(3):566-574. PubMed ID: 32533509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association between clinical and tumor features with postoperative thyroglobulin in pediatric papillary thyroid cancer.
    Tian T; Jiang L; Zhang X; Huang R; Liu B
    Surgery; 2020 Dec; 168(6):1095-1100. PubMed ID: 32948335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.